# rbGyanX-genius evolved Clinical Validation Protocol

## Executive Summary

This document outlines the comprehensive clinical validation protocol for rbGyanX-genius evolved, a mobile application for radiobiology and dosimetry calculations in radiation oncology. The protocol ensures scientific rigor, regulatory compliance, and publication readiness for peer-reviewed medical journals.

## 1. Study Design

### 1.1 Study Type
**Prospective Validation Study** - Comparative analysis of rbGyanX-genius evolved calculations against established clinical benchmarks and published literature data.

### 1.2 Primary Objectives
- Validate accuracy of TCP and NTCP calculations against published clinical data
- Demonstrate clinical utility and workflow integration in radiation oncology departments
- Establish safety and reliability for clinical decision support
- Demonstrate compliance with QUANTEC and RTOG guidelines

### 1.3 Secondary Objectives
- Assess user experience and clinical adoption
- Evaluate computational performance and scalability
- Validate DICOM-RT parsing and DVH extraction accuracy
- Assess multi-user collaboration features in clinical workflows

## 2. Validation Methodology

### 2.1 Calculation Accuracy Validation

**Benchmark Comparison:**
- Compare rbGyanX-genius evolved TCP/NTCP outputs against published clinical trial data
- Validate against established radiobiological models (Niemierko, Lyman-Kutcher-Burman)
- Cross-validate with commercial treatment planning systems (TPS)
- Test against published case studies from peer-reviewed literature

**Test Cases:**
- Minimum 50 clinical cases across different tumor sites:
  * Head & Neck (15 cases)
  * Prostate (15 cases)
  * Lung (10 cases)
  * Breast (5 cases)
  * Rectum (5 cases)

**Acceptance Criteria:**
- TCP/NTCP calculations within ±5% of published values
- DVH dose metrics (Vxx, Dxx) within ±2% of TPS values
- BED/EQD2 calculations within ±3% of published values
- All model parameters match QUANTEC recommendations

### 2.2 DICOM-RT Parsing Validation

**Test Protocol:**
- Parse DICOM-RT files from 10+ different treatment planning systems
- Validate structure extraction accuracy
- Verify dose grid interpolation
- Test DVH reconstruction from dose grids

**Acceptance Criteria:**
- 100% successful parsing of valid DICOM-RT files
- Structure names correctly identified and mapped
- DVH reconstruction within ±1% of original TPS values
- Graceful error handling for malformed files

### 2.3 Clinical Workflow Integration

**User Testing:**
- 20-30 medical physicists and radiation oncologists
- Real-world case analysis using rbGyanX-genius evolved
- Workflow efficiency assessment
- User satisfaction surveys

**Metrics:**
- Time to complete calculation (target: <5 minutes)
- User interface clarity (satisfaction >80%)
- Clinical decision support value (>75% found useful)
- Integration with existing workflows (>70% positive)

## 3. Data Management & Privacy

### 3.1 Data Handling
- All patient data anonymized before analysis
- HIPAA/GDPR compliant data storage and transmission
- End-to-end encryption for sensitive data
- Secure deletion protocols for study completion

### 3.2 Informed Consent
- Comprehensive informed consent form (ICF)
- Clear disclosure of data usage and publication plans
- Participant right to withdraw at any time
- Confidentiality assurances

### 3.3 Data Security
- Role-based access control (RBAC)
- Audit logging of all data access
- Multi-factor authentication for administrators
- Regular security audits and penetration testing

## 4. Statistical Analysis

### 4.1 Primary Analysis
- Bland-Altman plots comparing rbGyanX-genius evolved vs. benchmark values
- Intraclass correlation coefficient (ICC) for agreement
- Mean absolute percentage error (MAPE) calculation
- 95% confidence intervals for all estimates

### 4.2 Subgroup Analysis
- Stratified analysis by tumor site
- Analysis by dose/fractionation scheme
- Analysis by model type (LKB Log-Logistic, Probit, Poisson)

### 4.3 Sensitivity Analysis
- Impact of parameter uncertainty on TCP/NTCP
- Robustness to DVH reconstruction errors
- Sensitivity to α/β ratio variations

## 5. Regulatory Compliance

### 5.1 FDA Classification
- Software as a Medical Device (SaMD) - Class II
- Clinical Decision Support Software
- Non-diagnostic, advisory function

### 5.2 Regulatory Documentation
- 510(k) submission (if required by jurisdiction)
- Clinical validation report
- Risk analysis and mitigation
- Software verification and validation (V&V) documentation

### 5.3 Quality Management System
- ISO 13485 compliance (Medical Device Quality Management)
- Design controls and design history file (DHF)
- Risk management per ISO 14971
- Post-market surveillance plan

## 6. Publication Strategy

### 6.1 Target Journals
- **Primary:** International Journal of Radiation Oncology Biology Physics
- **Secondary:** Physics in Medicine & Biology, Medical Physics
- **Alternative:** Radiotherapy and Oncology, Journal of Medical Physics

### 6.2 Manuscript Structure
1. **Introduction** - Clinical need and background
2. **Methods** - Validation protocol, statistical analysis
3. **Results** - Accuracy metrics, clinical validation, user feedback
4. **Discussion** - Clinical implications, limitations, future work
5. **Conclusion** - Summary and recommendations

### 6.3 Supplementary Materials
- Detailed calculation algorithms
- DICOM parsing specifications
- Complete validation dataset (anonymized)
- User interface screenshots
- Clinical workflow diagrams

## 7. Ethical Considerations

### 7.1 IRB Approval
- Institutional Review Board (IRB) approval required
- Protocol number and approval date documentation
- Continuing review schedule (annual minimum)
- Adverse event reporting procedures

### 7.2 Informed Consent
- Participants informed of study objectives
- Clear explanation of data usage
- Publication and sharing plans disclosed
- Voluntary participation emphasized

### 7.3 Conflict of Interest
- Disclosure of funding sources
- Declaration of competing interests
- Transparency in data handling and analysis

## 8. Implementation Timeline

| Phase | Duration | Milestones |
|-------|----------|-----------|
| **IRB Approval** | 2-4 weeks | Protocol submission, review, approval |
| **Data Collection** | 3-6 months | Recruit participants, conduct validation |
| **Analysis** | 2-3 months | Statistical analysis, manuscript preparation |
| **Peer Review** | 3-6 months | Journal submission, revision, acceptance |
| **Publication** | 1-2 months | Final publication and dissemination |

## 9. Success Criteria

### 9.1 Validation Success
- ✓ TCP/NTCP accuracy within ±5% of benchmarks
- ✓ 100% successful DICOM-RT parsing
- ✓ User satisfaction >80%
- ✓ Clinical utility confirmed by >75% of users

### 9.2 Publication Success
- ✓ Accepted by peer-reviewed medical journal
- ✓ Positive reviewer feedback on methodology
- ✓ Clinical impact recognized by community
- ✓ Cited in subsequent radiobiology research

## 10. Post-Publication Activities

### 10.1 Dissemination
- Conference presentations (ASTRO, AAPM, ICCR)
- Webinar series for clinical education
- Open-source release (if applicable)
- Community engagement and feedback

### 10.2 Continuous Improvement
- Collect user feedback post-publication
- Implement feature enhancements based on clinical feedback
- Conduct periodic validation updates
- Maintain regulatory compliance

### 10.3 Long-term Support
- Establish user community forum
- Provide clinical support and training
- Maintain software security and updates
- Plan for future research collaborations

## 11. References

[1] Niemierko, A. (1997). Reporting and analyzing dose distributions: A concept of equivalent uniform dose. Journal of Radiation Oncology Biology Physics, 37(1), 207-213.

[2] Lyman, J.T. (1985). Complication probability as assessed from dose-volume histograms. Radiation Research, 104, S13-S19.

[3] Kutcher, G.J., Burman, C., & Brewster, L. (1991). Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. International Journal of Radiation Oncology Biology Physics, 21(1), 137-146.

[4] Bentzen, S.M., Constine, L.S., & Deasy, J.O. (2010). Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An introduction to the scientific issues. International Journal of Radiation Oncology Biology Physics, 76(3), S3-S9.

[5] Emami, B., Lyman, J., Brown, A., et al. (1991). Tolerance of normal tissue to therapeutic irradiation. International Journal of Radiation Oncology Biology Physics, 21(1), 109-122.

[6] RTOG Foundation. (2024). Radiation Therapy Oncology Group Clinical Trials. Retrieved from https://www.rtog.org

---

**Document Version:** 1.0  
**Last Updated:** January 2, 2025  
**Status:** Ready for IRB Submission
